Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Manitoba

$17,500.00

"Investigation of vaccine-induced antibody levels and protection 15 to 18 years following primary hepatitis B virus vaccination in Arviat, Nunavut"

EF 2016-17

Résumé
Hepatitis B virus (HBV) is a globally recognized health problem leading to chronic infection in 5% of the world's population. Chronically infected individuals are at high risk for the development of severe complications including end-stage liver disease and hepatocellular carcinoma. In particular, the burden of viral hepatitis among Canadian Indigenous populations is disproportionately greater relative to their non-Indigenous counterparts. In Northern regions including Nunavut, the prevalence of HBV infection historically reached endemic rates until the initiation of an infant vaccination schedule in 1995. Although the incidence of infection declined considerably since this time, the duration of protection afforded by the HBV vaccine remains unknown. To determine the longevity of immune protection, the persistence of vaccine-induced antibody in 15 to 18 year old adolescents residing in Arviat, Nunavut that were vaccinated in infancy will be investigated. A booster dose will be provided and the immune memory response will be evaluated 30 days following. In parallel, the potential to use dried blood spot (DBS) sampling in place of serum samples to quantify the immune response will be assessed. Given that the level of vaccine-based immunity has likely declined rapidly in this population, it is crucial to ensure that an immune memory response is available to individuals who may be at increased risk for HBV exposure. The results from this study will assist in an evaluation of the current vaccination protocols and the potential for a fourth dose to be recommended to the vaccination schedule. Finally, the validation of DBS could prove indispensable to future serological surveys and aid in the proper assessment of vaccine coverage.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
367251
Name
Morriseau Taylor S
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
"Investigation of vaccine-induced antibody levels and protection 15 to 18 years following primary hepatitis B virus vaccination in Arviat, Nunavut"
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adolescent; Anamnestic Response; Circumpolar Arctic; Dried Blood Spot; Hepatitis B Virus; Inuit; Nunavut; Prevention; Vaccination
Abstract
Hepatitis B virus (HBV) is a globally recognized health problem leading to chronic infection in 5% of the world's population. Chronically infected individuals are at high risk for the development of severe complications including end-stage liver disease and hepatocellular carcinoma. In particular, the burden of viral hepatitis among Canadian Indigenous populations is disproportionately greater relative to their non-Indigenous counterparts. In Northern regions including Nunavut, the prevalence of HBV infection historically reached endemic rates until the initiation of an infant vaccination schedule in 1995. Although the incidence of infection declined considerably since this time, the duration of protection afforded by the HBV vaccine remains unknown. To determine the longevity of immune protection, the persistence of vaccine-induced antibody in 15 to 18 year old adolescents residing in Arviat, Nunavut that were vaccinated in infancy will be investigated. A booster dose will be provided and the immune memory response will be evaluated 30 days following. In parallel, the potential to use dried blood spot (DBS) sampling in place of serum samples to quantify the immune response will be assessed. Given that the level of vaccine-based immunity has likely declined rapidly in this population, it is crucial to ensure that an immune memory response is available to individuals who may be at increased risk for HBV exposure. The results from this study will assist in an evaluation of the current vaccination protocols and the potential for a fourth dose to be recommended to the vaccination schedule. Finally, the validation of DBS could prove indispensable to future serological surveys and aid in the proper assessment of vaccine coverage.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Morriseau, Taylor S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~